- Vaccine Name: Pediarix
- Target Pathogen: Poliovirus
- Target Disease: Polio
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined
- Tradename: Pediarix
- Manufacturer: GlaxoSmithKline
- Vaccine Ontology ID: VO_0000082
- CDC CVX code: 110
- Type: Subunit vaccine + Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: USA (License #1617), Canada
- Host Species for Licensed Use: Human
- Adjuvant:
- Preservative: 2 phenoxy ethanol
- Allergen: Polymyxin B Neomycin, Latex in plunger stopper of prefilled syringe
- Immunization Route: Intramuscular injection (i.m.)
- Storage: The vaccine should be refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze.
- Approved Age for Licensed Use: PEDIARIX is indicated for active immunization against diphtheria, tetanus, pertussis (whooping cough), all known subtypes of hepatitis B virus, and poliomyelitis caused by poliovirus Types 1, 2, and 3 as a three-dose primary series in infants born of HBsAg-negative mothers, beginning as early as 6 weeks of age. PEDIARIX should not be administered to any infant before the age of 6 weeks, or to individuals 7 years of age or older (FDA: Pediarix).
- Description: Products: Proteins + killed virus. Other components: Yeast protein Formaldehyde, Polysorbate 80.
|
